{"keywords":["EGFR mutation","Neuron specific enolase","Non-small cell lung cancer","Small cell lung cancer transformation"],"meshTags":["Adenocarcinoma","Aged, 80 and over","Cell Transformation, Neoplastic","Humans","Lung Neoplasms","Male","Phosphopyruvate Hydratase","Protein Kinase Inhibitors","Protein-Tyrosine Kinases","Receptor, Epidermal Growth Factor","Small Cell Lung Carcinoma","Tachyphylaxis"],"meshMinor":["Adenocarcinoma","Aged, 80 and over","Cell Transformation, Neoplastic","Humans","Lung Neoplasms","Male","Phosphopyruvate Hydratase","Protein Kinase Inhibitors","Protein-Tyrosine Kinases","Receptor, Epidermal Growth Factor","Small Cell Lung Carcinoma","Tachyphylaxis"],"genes":["serum neuron specific enolase","EGFR-tyrosine kinase","EGFR","EGFR","EGFR-tyrosine kinase","serum neuron specific enolase","NSE","EGFR","NSE"],"publicationTypes":["Case Reports","Journal Article"],"abstract":"We report the case of an 80-year-old male with relapsed EGFR exon 19 deletion lung adenocarcinoma treated with EGFR-tyrosine kinase inhibitor (TKI), but with poor response and rapid increase of serum neuron specific enolase (NSE). Repeat biopsy identified pathological transformation to small cell lung cancers (SCLC) retaining the same EGFR mutation. This case highlights routine serological testing of NSE may benefit for the lung adenocarcinoma patients resistant to TKIs. ","title":"Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?","pubmedId":"23683536"}